Is a Bubble Building in Large-Cap Biotechs?

Big cap biotechs Celgene (CELG), Biogen (BIIB), and Amgen (AMGN) have posted impressive gains in the past year that have all three trading at their highest valuation in years.

Mar 18, 2014 at 2:30PM

The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) has achieved an 81% return since February 2013, a return that trounces the S&P 500 index ETF's 26% return. By any measure, that's an astounding run, but does it signal a bubble has been built that's about to burst?

Let's take a look at three of the biggest biotech companies: Celgene (NASDAQ:CELG), Biogen (NASDAQ:BIIB), and Amgen (NASDAQ:AMGN). All three have made cork-popping moves in the past year that suggest they might be due for a pause.

CELG Chart

CELG data by YCharts

Pricing in perfection?
At all three companies, the price to sales ratio -- which shows how much investors are paying for every dollar of revenue -- are hitting new five year highs. That enthusiasm is tied to each company rolling out new therapies that are driving revenue higher.

Celgene has successfully launched Abraxane, a cancer compound already approved as a treatment for breast, lung, and pancreatic cancers. Abraxane's sales jumped 90% in the past year to $202 million in the fourth quarter. Biogen rolled out Tecfidera last March as its first oral multiple sclerosis drug, and sales of the compound reached nearly $400 million last quarter.   And sales of Amgen's Prolia and Xgeva osteoporosis and cancer therapies were up 41% from last year to $522 million in the fourth quarter. 

AMGN PS Ratio (TTM) Chart

AMGN PS Ratio (TTM) data by YCharts

The success of those compounds have investors willing to pay up for earnings too. Biogen and Amgen's trailing 12 month price to earnings ratio are at their highest levels in five years, and Celgene's is at a three year high.

CELG PE Ratio (TTM) Chart

CELG P/E Ratio (TTM) data by YCharts

Looking into the future
The price to sales and price to earnings ratios suggest that investors are frothier today than they've been in years. However, both those measures are looking at how investors are valuing the companies on yesterday's results, not tomorrow's. Since markets are forward looking instruments, it may be helpful to instead consider how the three are valued using future sales and earnings estimates that take into consideration the potential for compounds like Abraxane, Tecfidera, and Prolia/Xgeva.

In the case of the companies' forward price to sales ratio, the measure is similar to the historical data, with investors paying more for future sales than they have in five years. But earnings are arguably more important given they're a better reflection of how efficiently companies operate and how likely companies will be to stay shareholder friendly. Unfortunately for bulls, all three companies' future price to earnings ratios are also lofty. To find a similar period where investors were willing to pay as much for future earnings you'd need to go back to the pre-recession peak. That suggests the potential for these fast-growing drugs may already be reflected by current share prices.

CELG PE Ratio (Forward) Chart

CELG P/E Ratio (Forward) data by YCharts

Fool-worthy final thoughts
Celgene, Biogen, and Amgen all appear to be a bit pricey based on where they've been in the past five years, but that doesn't necessarily mean they're in a bubble. No one can predict where the market will go in the short term. After all, markets have a tendency to surprise investors both on the way up and the way down.

That suggests investors shouldn't base their decision on whether to own these companies solely on their valuation, but also on their patent risks, FDA filings, and drugs making their way through their pipelines. If Celgene can successfully usher its potential psoriasis drug Apremilast through the FDA, Tecfidera can win over price hawks in Europe, and Amgen can win approval for a new therapy that could eventually alter how doctors treat high cholesterol, then share prices may not be as expensive as they appear. As a result, investors should not only consider the valuation risk, but also keep a close eye on regulatory filings and approvals before making a decision on whether to sell.

2014's must-have top stock
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisor's, LLC. Gundalow's clients do not have positions in the companies mentioned.

The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers